Scholar Rock, LLC

Eli Lilly’s muscle building drug candidate, bimagrumab, has exceeded expectations in a Phase IIb study, but analysts want to know more about its planned path to approval before getting too excited. Th

Scholar Rock’s myostatin inhibitor apitegromab helped preserve lean mass in individuals taking Lilly’s GIP/GLP-1 agonist tirzepatide for weight loss in a Phase II trial, a new potentially large commer

The European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12